Oceanside, California USA, Aug 16 – AOTI Inc. announced today the U.S. Patent and Trademark Office have granted its Patent Application No. 14/150,178 –
CONTROLLER FOR AN EXTREMITY HYPERBARIC DEVICE that will now issue as U.S. Patent No. 9,421,147. This is the 24th global patent to be awarded to date on AOTI’s revolutionary Topical Wound Oxygen (TWO2) therapy devices.
“This latest patent issuance further asserts the uniqueness of our Topical Wound Oxygen (TWO2) therapy approach and will help us provide this limb saving therapy to patients worldwide” stated Dr. Mike Griffiths, CEO and President of AOTI.
[if !supportLineBreakNewLine]
[endif]
“We are delighted that our Intellectual Property portfolio continues to expand globally, differentiating our unique Topical Wound Oxygen (TWO2) therapy from all others, as we strive hard to bring our products to market” added Griffiths.
About AOTI
AOTI Inc. is a leading international company providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TW O2) therapy is unsurpassed in completely healing Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Oceanside, California USA and Galway, Ireland with offices throughout the globe. For more information, see www.aotinc.net
